Simplex Trading, LLC Humanigen, Inc Transaction History

Simplex Trading, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$0.13 - $0.2 $349 - $537	-2,689 Reduced 42.09%	3,700 $0
Q1 2023 Apr 27, 2023	SELL	$0.12 - $0.23 $7,927 - $15,193	-66,059 Reduced 91.18%	6,389 $0
Q4 2022 Feb 02, 2023	SELL	$0.09 - $0.2 $139 - $309	-1,547 Reduced 2.09%	72,448 $8,000
Q3 2022 Nov 04, 2022	BUY	$0.15 - $3.02 $11,099 - $223,464	73,995 New	73,995 $13,000
Q2 2022 Aug 03, 2022	SELL	$1.76 - $3.33 $299,233 - $566,163	-170,019 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$1.81 - $3.97 $173,863 - $381,346	96,057 Added 129.87%	170,019 $511,000
Q4 2021 Feb 23, 2022	BUY	$3.66 - $8.22 $194,064 - $435,849	53,023 Added 253.23%	73,962 $275,000
Q3 2021 Oct 28, 2021	BUY	$5.93 - $17.83 $4,744 - $14,263	800 Added 3.97%	20,939 $357,000
Q2 2021 Aug 12, 2021	SELL	$13.54 - $22.74 $197,386 - $331,503	-14,578 Reduced 41.99%	20,139 $350,000
Q1 2021 Apr 26, 2021	BUY	$12.91 - $23.83 $247,226 - $456,344	19,150 Added 123.02%	34,717 $663,000
Q4 2020 Feb 02, 2021	BUY	$7.97 - $21.66 $124,068 - $337,181	15,567 New	15,567 $272,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.